Integrated Filing — IndAS



General information about company
Scrip Code 540797
NSE Symbol SHALBY
MSEI Symbol NOTLISTED
ISIN INE597J01018
Name of company SHALBY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 29-May-2025   17:20:00
End date and time of board meeting 29-May-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2648920000 10869550000
Other income 53200000 275960000
Total income 2702120000 11145510000
2 Expenses
(a) Cost of materials consumed 223080000 926910000
(b) Purchases of stock-in-trade 276310000 1039180000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -134910000 -820020000
(d) Employee benefit expense 448070000 1845820000
(e) Finance costs 106690000 387130000
(f) Depreciation, depletion and amortisation expense 162290000 657600000
(f) Other Expenses
1 Materials and Consumables 398750000 1686230000
2 Fees to Doctors and Consultants 685540000 2608070000
3 Other Operative expenses 206920000 909330000
4 Other Expenses 336770000 1347970000
Total other expenses 1627980000 6551600000
Total expenses 2709510000 10588220000
3 Total profit before exceptional items and tax -7390000 557290000
4 Exceptional items 0 0
5 Total profit before tax -7390000 557290000
6 Tax expense
7 Current tax 102720000 565260000
8 Deferred tax 11770000 -27170000
9 Total tax expenses 114490000 538090000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -121880000 19200000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -121880000 19200000
17 Other comprehensive income net of taxes 3650000 -26080000
18 Total Comprehensive Income for the period -118230000 -6880000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent -110150000 62220000
Total profit or loss, attributable to non-controlling interests -11730000 -43020000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent -106780000 35840000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -11450000 -42740000
21 Details of equity share capital
Paid-up equity share capital 1074870000 1074870000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 8847000000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0 0
Diluted earnings (loss) per share from continuing operations 0 0
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -1.13 0.18
Diluted earnings (loss) per share from discontinued operations -1.13 0.18
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -1.13 0.18
Diluted earnings (loss) per share from continuing and discontinued operations -1.13 0.18
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above Consolidated financial results for the quarter and year ended March 31 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on May 29 2025. The Statutory Auditors of the Company have expressed unmodified opinion on the aforesaid results. n n2.These financial results have been prepared in accordance with Indian Accounting Standards Ind AS as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies Indian Accounting Standards Rules 2015 and relevant amendment thereafter. n n3.The figures for quarter ended 31st March 2025 and for corresponding quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year to date figures up to the third quarter of the respective financial year. n n4.Shalby Limited Employees Welfare Trust has acquired 700000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme2021. During the quarter ended March 31 2025 the Company has granted 205265 Stock Options to eligible employees. Till March 31 2025 Company has granted all 700000 Stock Options to eligible employees out of which total 313265 Stock Options were lapsed and 177235 Options were vested and exercised by eligible employees. n nIn accordance with the resolution passed by the Nomination and Remuneration Committee the Company has granted 9000 stock options from the pool of 313265 lapsed options and as of March 31 2025 a total of 218500 stock options remain active. n n5.During the previous year the Company has acquired 87.26 percent stake in shareholding of PK Healthcare Private Limited through preferential allotment of equity shares and secondary acquisition from promoters during January 2024. PK Healthcare Pvt. Ltd. is now a subsidiary of the Company Effective form 25th January 2024. n n6.During the previous year the Company has acquired 100 percent stake in shareholding of Healers Hospital Private Limited through secondary acquisition from existing shareholders during March 2024. Healers Hospital Pvt. Ltd. is now wholly owned subsidiary of the Company effective from 15th March 2024. n n7. Shalby Advanced Technologies Inc. USA stepdown subsidiary of the Company has incorporated its subsidiary in India namely Shalby Advanced Technologies India Pvt. Ltd on 11th April 2024 n n8. The consolidated financial result includes the results of the Company and 14 Subsidiary companies including 4 stepdown subsidiaries. The company together with its subsidiaries is herein referred to as the Group. n n9.The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular dated 26th November 2018. n n10. The Code on Social Security 2020 relating to employee benefits during employment and postemployment benefits has received Presidential assent and has been published in the Gazette of India. However the effective date of the Code and final rules for quantifying the financial impact are yet to be notified. The Group will assess the impact of the Code when relevant provisions are notified and will record related impact if any in the period the Code becomes effective. n n11.As per Indian Accounting Standard Ind AS 108 Segment Reporting segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Healthcare Activities Manufacturing of Implant. Disclosure for the same is given in the separate note attached herewith in Annexure I. n n12. Previous period figures have been regrouped recast and rearranged wherever considered necessary to make it comparable. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 8481710000
Capital work-in-progress 80420000
Investment property 0
Goodwill 568590000
Other intangible assets 503660000
Intangible assets under development 139240000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 224150000
Total non-current financial assets 224150000
Deferred tax assets (net) 67150000
Other non-current assets 392000000
Total non-current assets 10456920000
2 Current assets
Inventories 3192110000
Current financial asset
Current investments 946280000
Trade receivables, current 1752130000
Cash and cash equivalents 347850000
Bank balance other than cash and cash equivalents 770000
Loans, current 0
Other current financial assets 108980000
Total current financial assets 3156010000
Current tax assets (net)
Other current assets 231490000
Total current assets 6579610000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 17036530000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1074880000
Other equity 8847000000
Total equity attributable to owners of parent 9921880000
Non controlling interest 31390000
Total equity 9953270000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1366690000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 3470000
Total non-current financial liabilities 1370160000
Provisions, non-current 60040000
Deferred tax liabilities (net) 631350000
Deferred government grants, Non-current 0
Other non-current liabilities 468470000
Total non-current liabilities 2530020000
Current liabilities
Current financial liabilities
Borrowings, current 2900490000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 39660000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1144550000
Total Trade payable 1184210000
Other current financial liabilities 187340000
Total current financial liabilities 4272040000
Other current liabilities 245540000
Provisions, current 35660000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 4553240000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 7083260000
Total equity and liabilites 17036530000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Healthcare Services 2372560000 9797850000
2 Manufacturing of Implants 276360000 1071700000
Total Segment Revenue 2648920000 10869550000
Less: Inter segment revenue
Revenue from operations 2648920000 10869550000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Healthcare Services 158930000 960640000
2 Manufacturing of Implants -166320000 -403350000
Total Profit before tax -7390000 557290000
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax -7390000 557290000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Healthcare Services 13530030000 13530030000
2 Manufacturing of Implants 3506510000 3506510000
Total Segment Asset 17036540000 17036540000
Un-allocable Assets 0 0
Net Segment Asset 17036540000 17036540000
4 Segment Liabilities
Segment Liabilities
1 Healthcare Services -3321920000 -3321920000
2 Manufacturing of Implants -3761350000 -3761350000
Total Segment Liabilities -7083270000 -7083270000
Un-allocable Liabilities 0 0
Net Segment Liabilities -7083270000 -7083270000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -3610000 -950000
Total Amount of items that will not be reclassified to profit and loss -3610000 -950000
2 Income tax relating to items that will not be reclassified to profit or loss -2030000 -1120000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss -5230000 26250000
5 Total Other comprehensive income 3650000 -26080000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 557290000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 387130000
Adjustments for decrease (increase) in inventories -840090000
Adjustments for decrease (increase) in trade receivables, current -310590000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -131690000
Adjustments for decrease (increase) in other non-current assets 15860000
Adjustments for other financial assets, non-current 37590000
Adjustments for other financial assets, current 16580000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -82110000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -14910000
Adjustments for increase (decrease) in other non-current liabilities -17030000
Adjustments for depreciation and amortisation expense 657600000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 20400000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 780000
Adjustments for other financial liabilities, non-current -600000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 72250000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -80410000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -44590000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -458330000
Net cash flows from (used in) operations 98960000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 142380000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -43420000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 13610000
Purchase of property, plant and equipment 714460000
Proceeds from sales of investment property 5193420000
Purchase of investment property 5248510000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 77170000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 322400000
Net cash flows from (used in) investing activities -356370000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 750000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 1520680000
Repayments of borrowings 393050000
Payments of lease liabilities 176200000
Dividends paid 129610000
Interest paid 347360000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 630000
Net cash flows from (used in) financing activities 475840000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 76050000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 76050000
Cash and cash equivalents cash flow statement at beginning of period 271810000
Cash and cash equivalents cash flow statement at end of period 347860000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 T R CHADHA & CO. LLP Yes 30-Sep-2025